Coronary Artery Disease Progression Clinical Trial
Official title:
Relation Among Cholesterol Uptake Capacity Which Measure HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization After Stent Implantation
NCT number | NCT03540381 |
Other study ID # | KobeU-152M816M |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2011 |
Est. completion date | July 31, 2017 |
Verified date | May 2018 |
Source | Kobe University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this study is to evaluate the relation among cholesterol uptake capacity which measure HDL functionality, neoathrosclerosis and target-lesion revascularization.
Status | Completed |
Enrollment | 181 |
Est. completion date | July 31, 2017 |
Est. primary completion date | July 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of coronary artery disease - Patients who had undergone percutaneous coronary intervention - Patients who had been treated with bare-metal stents, drug-eluting stents - Patients who had successfully undergone follow-up OCT for the target stents >6 months after stenting. Exclusion Criteria: - The stent was implanted in the left main trunk - OCT images were of insufficient quality |
Country | Name | City | State |
---|---|---|---|
Japan | Kobe University Graduate School of Medicine, Department of Cardiology | Kobe | Hyogo |
Lead Sponsor | Collaborator |
---|---|
Kobe University |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cholesterol Uptake Capacity (CUC) | CUC is a new rapid cell-free assay system to evaluate the functional capacity of HDL to accept additional cholesterol | an average of a year and a half |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05462262 -
Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population
|
N/A | |
Not yet recruiting |
NCT06040073 -
Natural History of Coronary Atherosclerosis
|
||
Active, not recruiting |
NCT03349385 -
Registry of Secondary Revascularization
|
||
Recruiting |
NCT05860400 -
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
|
||
Recruiting |
NCT05783804 -
Plaque Reversal With Early, Aggressive Lipid Lowering Therapy
|
||
Completed |
NCT03192579 -
Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial
|
Phase 4 | |
Completed |
NCT03195621 -
Critical Treatment of Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05800093 -
Proteomics and Genomics Combined With CT to Predict CVD
|
||
Recruiting |
NCT03533959 -
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy
|
||
Recruiting |
NCT04772768 -
Prior CABG Patients Evaluated for Saphenous VeIn grAft DysfUnction and Progression of Coronary arTery Disease
|
||
Not yet recruiting |
NCT06007248 -
Disease Characteristics of IR-CAD: a Case-control Study
|
||
Recruiting |
NCT03943459 -
Sirtuin-1 and Advanced Glycation End-products in Postmenopausal Women With Coronary Disease
|
Phase 3 | |
Recruiting |
NCT03788369 -
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
|